NCT07415837Recruiting
Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases. MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease. The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities: 1. Patients with Duchenne or Becker muscular dystrophy (DMD/DMB). 2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease). 3. Patients with congenital myopathies. 4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- First submitted
- 10 Feb 2026
- Start date
- 11 Feb 2026
- Primary completion date
- Mar 2029
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Duchenne muscular dystrophy
- NCT number
- NCT07415837
What you commit to
- Study type: Interventional
- Planned participants: 104
- From 11 Feb 2026 to the primary completion date, Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Engaging in intense and unusual physical effort within 10 days before the blood draw.
- Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results.
Other
- Refusal to participate expressed by the subject or their parental authority.
- Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection.
- Women who are pregnant or breastfeeding.
- The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings
Who the study is looking for
- Age: Participants must be older than 2 years of age
- Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,.
- Social Security: Every participant must be affiliated with the French social security system.
- Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.
Age in the registry: 2 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.